Cytokinetics, Incorporated (CYTK)

65.90 +0.85 (+1.31%) 市場開市。 截至 03:34PM EDT。

Cytokinetics, Incorporated

350 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 624 3000
https://www.cytokinetics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 423

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Robert I. Blum	CEO, President, Principal Financial Officer & Director	1.33M	9.61M	1964
Mr. Robert C. Wong	VP & Chief Accounting Officer	495.72k	無	1968
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.	Executive Vice President of Research & Development	839.66k	586.17k	1964
Mr. Andrew M. Callos	Executive VP & Chief Commercial Officer	752.84k	無	1969
Dr. James A. Spudich Ph.D.	Co-Founder & Member of Scientific Advisory Board	21.94k	無	1942
Mr. Jeff Lotz	Vice President of Sales & Operations	無	無	無
Mr. Matt Yang	Vice President of Corporate Finance and Financial Planning & Analysis	無	無	無
Mr. Steven M. Cook	Senior Vice President of Global Supply Chain Operations & Technical Operations	無	無	1959
Ms. Kari K. Loeser J.D.	VP & Chief Compliance Officer	無	無	無
Mr. John O. Faurescu Esq.	VP, Associate General Counsel & Corporate Secretary	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

公司管治

截至 2024年5月1日 止，Cytokinetics, Incorporated 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：2；董事會：3；股東權利：7；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。